ReviewBiomolecules2021
Accumulation of CD28
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Low intensity vibration as a novel strategy to normalize age-related deficits in T cell proliferation, activation, and function.Scientific reports · 2026Article
- Effect of prevaccination blood and T-cell phenotypes on antibody responses to a COVID-19 mRNA vaccine.International immunology · 2025Article
- Aging and Inflammation.Cold Spring Harbor perspectives in medicine · 2024Review
- Excess of body weight is associated with accelerated T-cell senescence in hospitalized COVID-19 patients.Immunity & ageing : I & A · 2024Article
- Article
- Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization.Frontiers in immunology · 2024Review
- Suppressed transcript diversity and immune response in COVID-19 ICU patients: a longitudinal study.Life science alliance · 2024Article
- Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.Frontiers in immunology · 2024Article
- Spanish HCMV Seroprevalence in the 21st Century.Viruses · 2023Article
- Accelerated T-Cell Immunosenescence in Cytomegalovirus-Seropositive Individuals After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.The Journal of infectious diseases · 2023Article
- The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.International journal of molecular sciences · 2023Article
- Comprehensive immune profiling of SARS-CoV-2 infected kidney transplant patients.Frontiers in transplantation · 2023Article
- Machine learning of flow cytometry data reveals the delayed innate immune responses correlate with the severity of COVID-19.Frontiers in immunology · 2023Article
- Cellular senescence and the tumour microenvironment.Molecular oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Coronavirus disease 2019 (COVID-19), a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes infectious disease, and manifests in a wide range of symptoms from asymptomatic to severe illness and even death. Severity of infection is related to many risk factors, including aging and an array of underlying conditions, such as diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and cancer. It remains poorly understood how these conditions influence the severity of COVID-19. Expansion of the CD28
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.